Wednesday, June 25, 2008

The Arizona Bioscience Experience in New Mexico

Biotech News

The Arizona Bioscience Experience in New Mexico

Guest Speaker Robert Eaton,

President and CEO of Arizona Bio

"The Arizona Bioscience Experience" on July 8th

Bob Eaton serves as CEO of AZ Bio, the Ariziona Bioindustry Association which he joined in October, 2007. During his short time with AZ Bio, Bob has already succesfully merged the State's regional bioscience groups into a single, strong Statewide association, and has begun an aggressive drive to expand membership.

Previously, Bob served for ten years as president of MdBio where he expanded the nonprofit organization from a staff of two to eight with an annual operating budget of about $2 million. He managed the investment of approximately $4 million in more than 30 bioscience companies, and has worked closely with senior biotechnology and pharmaceutical industry leaders regarding state and federal regulatory and policy issues. Under his leadership, MdBio developed an array of programs to support the growth andsuccess of bioscience companies, primarily in theareas of business development, communication, workforce training, and K-12 education.

In previous roles, Eaton worked with the Technology Council of Maryland, where he worked with industry leaders to establish the Maryland Bioscience Alliance; served as director of R&D programs for the Pharmaceutical Manufacturers Association (now PhRMA) in Washington, D.C.; worked with a small molecular biology services company; and was involved in protein biochemistry research at the National Institutes of Health.

Eaton also served on several boards and councils in Maryland and Virginia related to the bioscience and technology industries. He received a master's degree in science, technology, and public policy from George Washington University and a bachelor's degree in applied and engineering physics from Cornell University.

NMBio July Meeting: Bob Eaton of AZ Bio
Date: Tuesday, July 8th, 2008
UNM STC Rotunda
11:30 am to 1:00 pm
Cost: $25.00 NMBBA Members
$35.00 Non-Members

RSVP to Annie Hooten at anniehooten@aol.com
by Friday Noon, July 4th, 2008 or register using the PayPal links above.

Prepayment is required by either check or credit card (M/C or VISA only) to reserve. Send checks to NMBio, P.O. Box 80233, Albuquerque, NM 87198
AZhttp, Inc.
Biotechnology Marketing

Saturday, June 14, 2008

State-of-the-Art Biotechnology Equipment Hits the Auction Block

Biotech News
AZhttp, Inc.

State-of-the-Art Biotechnology Equipment Hits the Auction Block

Cowan Alexander ramps up for live webcast equipment auction for Nucleonics and Amphora Discovery.

June 13, 2008 -- Cowan Alexander, LLC a leading biotechnology equipment auctioneer, today announced two Live Global Webcast equipment auctions. The first auction will take place Tuesday, June 17, 2008 at 11 a.m. EDT at Nucleonics in Horsham, PA; the second auction will take place Thursday, June 24, 2008 at 11:00 a.m. EDT at the Amphora Facility in Durham, NC. Equipment can be inspected the day prior at the respective facilities from 9 a.m. to 4 p.m. and the morning of the sale.

Equipment highlights from the Nucleonics sale include Gentinge 533LS vacuum/gravity sterilizers, Bioflow 3000 fermentor, Li-Cor Odyssey imaging system, Waters Alliance HPLC's, Berthold Centro XS3 luminometer, Microbiology System V.95 autoclave, Applied Biosystems 7500 PCR, Baker biosafety cabinets, assorted incubators and freezers, Sorvall and Eppendorf centrifuges, Molecular Devices SpectraMax 2 plate readers, Leica tissue prep and processing instrumentation, Olympus IMT-2 and IX71 microscopes, Pelicon 2 TFF and many more items. The Amphora Discover sale includes at Large Quantity of Caliper 250, Labchip 3000, Sciclone ALH3000 and Molecular Devices Ion Works HT liquid assay workstations plus general purpose lab support equipment, IT gear, facility equipment, office equipment and furniture and much more.

These auctions represent a tremendous buying opportunity for companies both large and small looking for quality equipment at auction price. All equipment will be sold regardless of price with no minimum bid and no reserve prices
"These auctions represent a tremendous buying opportunity for companies both large and small looking for quality equipment at auction price. All equipment will be sold regardless of price with no minimum bid and no reserve prices," said Don Cowan, president of Cowan Alexander.
The auction will also be broadcast live on the Internet, prospective buyers may bid live onsite or real-time on the web. For more information please visit www.cowanalexander.com.

About Cowan Alexander LLC
Cowan Alexander LLC is the nation's leading technology auction, capital recovery and valuation company. Cowan Alexander provides custom-tailored asset disposition and valuation services to technology investors, lenders and technology companies. This experienced team of professionals has successfully sold more than $1 billion in assets and has completed more than 1,000 valuation assignments worldwide. For more information, visit www.cowanalexander.com.

Biotechnology Marketing

Saturday, June 07, 2008

Leading U.S. Bioscience Pioneers Enter International Collaboration with Government of Luxembourg to Accelerate Biomedical Research

Biotech News
AZhttp, Inc.

Leading U.S. Bioscience Pioneers Enter International Collaboration with Government of Luxembourg to Accelerate Biomedical Research


International Public-Private Initiative to Drive Innovation in the U.S. and Overseas

06-05-2008

New York, June 6, 2008 - Three of the United States' most prominent biomedical science leaders have been tapped by the government of Luxembourg for an unprecedented international collaboration to establish a bioscience center of excellence in the heart of the European Union.
The government of the Grand Duchy of Luxembourg has announced an ambitious plan to increase the pace of innovation based on cutting-edge research in the areas of molecular biology, systems biology and personalized medicine. The initiative will include formation of a centralized biobank/tissue repository, two major projects to further research in the field of molecular biology, which is the cornerstone of personalized medicine, and a project to demonstrate the effectiveness of new diagnostics tests for earlier detection and treatment of lung cancer.

The U.S. organizations involved in the collaboration are: The Partnership for Personalized Medicine (PPM) led by Dr. Leland H. Hartwell, director, Nobel Laureate in Physiology or Medicine in 2001 and president of the Fred Hutchinson Cancer Research Center in Seattle, Washington; The Institute for Systems Biology (ISB), also in Seattle, led by Dr. Leroy Hood, president of ISB and co-founder of U.S.-based Amgen Inc.; and Arizona's Translational Genomics Research Institute (TGen), led by Dr. Jeffrey Trent, president and scientific director of TGen and former scientific director at the National Human Genome Research Institute of the National Institutes of Health.

The announcement was made jointly by three branches of Luxembourg's government, the Ministry of the Economy and Foreign Trade, the Ministry for Culture, Higher Education and Research and the Ministry of Health. The Luxembourg government is investing $200 million in the initiative, with the hope that ultimately it will improve the health of its own people by increasing the ability to administer the right drug to the right patient at the right time and in the right dose. In addition, it seeks to accelerate the global pace and integration of biomedical research, education and commercial development around the world.

The public-private initiative is expected to serve as a model for other international collaborations among partners looking to not only share research and development costs but also to gain access to each other's information, networks and markets. The Luxembourg collaboration was developed and negotiated in consultation with the global professional services organization, PricewaterhouseCoopers, and is built on an integrated approach that links research, education, healthcare and the economy.

The collaboration consists of three interrelated research initiatives that build on each other. They include:

Build the Integrated BioBank of Luxembourg (IBBL)
Led by TGen, Luxembourg will launch the Integrated BioBank of Luxembourg, which has the promise of becoming a premier European hub for advanced biobanking, biotechnology and biomedical informatics.

Biobanks are invaluable in bridging the gap between the pace of scientific and technological advancement and translation to clinical benefit. Most existing European and U.S. biobanks focus on simple collection and redistribution of specimens to scientists and educators. The IBBL will implement uniform standards for collection, storage and redistribution of an anticipated full range of tissue samples (e.g. blood, serum and tumor tissue). However, the added value of this next-generation biobank will be the detailed, centralized, molecular-based characterization of biospecimens, which over time (and ultimately linked to detailed clinical information) will lead to amassing an extensive database of medically relevant information.

The project will unite and leverage expertise in biology, pathology, informatics and information technology infrastructure, laboratory operations, transportation, legal matters and ethics.

Accessible to European and international colleagues, IBBL will maintain its collection of tissues in a research environment that will seek collaborations broadly within the wider research community. As such, the IBBL will serve as a centralized resource for sharing and comparing research results through a robust, scalable and secure bioinformatics system that supports the collection, processing, storage, annotation and distribution of biospecimens and data.

TGen's principal role working with Luxembourg scientists and physicians, will be to jointly develop and implement the next generation of molecular medicine through the development of the information architecture and technology implementation.

Create the Center for Systems Biology Luxembourg (CSBL)
The Institute for Systems Biology will collaborate with the University of Luxembourg to create the Center for Systems Biology Luxembourg. The Center will participate with ISB on two basic research projects designed to provide greater insight into the identification of disease and to enable more effective treatments:


ISB Research Project 1: The first project will include completion of a personalized human genome sequencing map on a minimum of one hundred subjects and development of new methods for understanding the role of genetic variations in disease, leading to new insights into diagnosis, treatment and prevention.
ISB Research Project 2: The second project is development of integrated systems proteomics, RNA and cell analysis methodology and tools based on ISB’s groundbreaking discovery of protein blood "fingerprints" and single-cell characteristics that can report on the physiological state of the body's 50 major organs. The research promises to lead to powerful early diagnostic approaches to not only treat but also predict disease and the ability to monitor the effects of existing drugs, including both effective responses or adverse reactions.
ISB's role will be to apply its systems biology approaches and tools to study model organisms such as mice to determine how best to interrogate and analyze human genetic data at the DNA sequence level. New computational and mathematical tools will be developed to facilitate these large-scale genome analyses and to integrate these insights with protein blood fingerprints.
Launch the Luxembourg Project Lung Cancer
The goal of Luxembourg Project Lung Cancer is to advance research in personalized medicine by pursuing research projects to develop molecular diagnostics for specific disease. These research projects center on the selection and validation of biomarkers to more effectively diagnose and manage disease from early detection through therapeutic follow-up.

The Luxembourg project will focus specifically on lung cancer for which there are no reliable tools for early detection and for patients with advanced disease with virtually no known cures. The project also will seek to demonstrate that earlier detection and intervention can reduce healthcare costs. The initiative capitalizes on the efforts of the U.S.-based Partnership for Personalized Medicine (PPM), led by Dr. Hartwell, and will develop use of new personalized, protein-based diagnostic tools.

The Partnership will unite the efforts and capabilities of investigators at TGen and the Biodesign Institute at Arizona State University, as well as the Fred Hutchinson Cancer Center in Seattle. Over time this effort is expected to link to a host of other research institutions and initiatives in the U.S. and beyond.

Personalized medicine focuses on improved prevention, targeted screening, early diagnosis and treatment of the causes of illness with drugs based on an individual's genetic and biological make-up, such as drugs targeted and suited to each patient. It is believed that personalized medicine will gradually take the place of conventional medicine. Ultimately, this will result in great improvements in the ability to administer the right drug to the right patient at the right time and in the right dose.

About the Institute for Systems Biology
Founded in 2000, the Institute for Systems Biology (ISB) is an internationally renowned, non-profit research institute headquartered in Seattle and dedicated to the study and application of systems biology. Founded by Leroy Hood, Alan Aderem and Ruedi Aebersold, ISB seeks to use systems methods to unravel the mysteries of human biology and identify strategies for predicting and preventing diseases such as cancer, diabetes and AIDS. ISB's systems approach integrates biology, computation and technological development, enabling scientists to analyze all elements in complex biological systems rather than one gene or protein at a time. For more information about ISB, visit www.systemsbiology.org.

About the Partnership for Personalized Medicine
The Partnership for Personalized Medicine is a major healthcare research initiative that unites contributions from two leading Arizona-based philanthropic organizations: the Virginia G. Piper Charitable Trust and the Flinn Foundation with leadership and research capabilities from Fred Hutchinson Cancer Research Center, the Translational Genomics Research Institute and the Biodesign Institute at Arizona State University.

About Fred Hutchinson Cancer Research Center
At Fred Hutchinson Cancer Research Center, interdisciplinary teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Hutchinson Center researchers, including three Nobel Laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, visit www.fhcrc.org.

About the Biodesign Institute at Arizona State University
The Biodesign Institute at ASU integrates diverse fields of science to cure and prevent disease, overcome the limitations of injury, renew the environment and improve national security. By fusing research in biology, engineering, medicine, physics, information technology and cognitive science, the institute accelerates discoveries into uses that can be adopted rapidly by the private sector. For more information, visit www.biodesign.asu.edu.

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process.

Biotechnology Marketing

Tuesday, June 03, 2008

TGen Researcher Receives the Young Investigator Award from the Arizona Alzheimer’s Consortium

Biotech News
AZhttp, Inc.

TGen Researcher Receives the Young Investigator Award from the Arizona Alzheimer’s Consortium


Dr. Matthew Huentelman honored for his contributions to Alzheimer's disease and aging research

06-03-2008

PHOENIX, AZ, JUNE 3, 2008--Dr. Matthew Huentelman, an Associate Investigator in the Neurogenomics Division at the Translational Genomics Research Institute (TGen), was the recipient of the Young Investigator Award from the Arizona Alzheimer’s Consortium. Dr. Huentelman was recognized for his pioneering accomplishments in Alzheimer’s disease research and for being an outstanding mentor to his research team and students.
"The Arizona Alzheimer's Consortium is extremely proud of Matt. He has already made significant contributions to the genetic understanding of memory and Alzheimer's disease, and to the discovery of promising memory-enhancing treatments. Matt's know-how and accomplishments, his dedication, hard work and enthusiasm, and his mentoring skills and collaborative spirit are examples for us all," said Dr. Eric Reiman, Director, Arizona Alzheimer's Consortium.

The Young Investigator Award is given annually to a young investigator in Arizona for their contributions to Alzheimer's disease and aging research. The selection process for the Young Investigator Award is extremely competitive. Each candidate is evaluated by the Arizona Alzheimer's Consortium's Internal Scientific Advisory Board, which consists of 25 researchers from the organization's seven institutional members.

"I really value my relationship with the Arizona Alzheimer's Consortium. There are many excellent young investigators within the Consortium, and I consider it a great honor to receive this award,” said Dr. Huentelman.

Dr. Huentelman received a plaque and a $5,000 research grant to continue his work in memory research. He accepted the award at the Consortium's annual meeting attended by fellow researchers, members of the community, the Consortium's Internal and External Advisory Boards, and the meeting's keynote speaker, Dr. David Holtzman, the Andrew B. and Gretchen P. Jones Professor and Chairman of the Department of Neurology at the Washington University School of Medicine.

"This is an outstanding honor for a terrific young scientist whose efforts are moving this field forward in remarkable ways,” said TGen President Dr. Jeffrey Trent.

Currently, Dr. Huentelman is using genetic technologies to study a gene called KIBRA, which plays a significant role in memory performance in humans. Dr. Huentelman has received grants from the National Institutes of Health and Science Foundation Arizona to continue this work with the hope of developing promising new Alzheimer's disease treatments.

Dr. Huentelman joined TGen in July of 2004 after completing his doctoral work at the University of Florida's Department of Physiology and Functional Genomics where he investigated the application of gene therapy in the study of hypertension. His undergraduate degree is from Ohio University's Department of Chemistry and Biochemistry. Dr. Huentelman's career includes visiting researcher stints in Moscow, Russia at the prestigious Lomonosov Moscow State University and in the United Kingdom at the University of Bristol. At present time he has published over 25 peer-reviewed manuscripts in the scientific literature.

The Arizona Alzheimer's Consortium is the nation’s leading model of statewide collaboration in Alzheimer's disease research. Established in 1998, the Consortium capitalizes on its participating institutions' complementary strengths in brain imaging computer science, genomics, the basic and cognitive neurosciences and clinical and neuropathology research to promote the scientific understanding and early detection of Alzheimer's disease and find effective disease-stopping and prevention therapies. It also seeks to educate Arizona residents about Alzheimer's disease, research progress in the state and the resources needed to help patients, families and professionals manage the disease. The Consortium is determined to find effective treatments to halt the progression and prevent the onset of Alzheimer's disease in the next 12 years

# # #

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen's vision is of a world where an understanding of genomic variation can be rapidly translated in a manner tailored to individual patients.

About the Arizona Alzheimer's Consortium
The Arizona Alzheimer's Consortium is a 501(c)(3) organization that includes the state-supported Arizona Alzheimer's Research Center (AARC), the National Institute on Aging (NIA)-funded Arizona Disease Core Center (Arizona ADCC), and independently funded research programs. Its seven member institutions include: Arizona State University, the Barrow Neurological Institute, the Mayo Clinic Arizona, the Sun Health Research Institute, the Translational Genomics Research Institute (TGen), the University of Arizona, and the Banner Alzheimer's Institute. Its three affiliated institutions include Banner Good Samaritan Medical Center, the Southern Arizona Veterans Administration Health Care System and the University Physician's Hospital at Kino.


Biotechnology Marketing